The parasitic worm product ES-62 promotes health- and life-span in a high calorie diet accelerated mouse model of ageing

Crowe, Jenny and Lumb, Felicity E. and Doonan, James and Broussard, Margaux and Tarafdar, Anuradha and Pineda, Miguel A. and Landabaso, Carmen and Mulvey, Lorna and Hoskisson, Paul A. and Babayan, Simon A. and Selman, Colin and Harnett, William and Harnett, Margaret M. (2020) The parasitic worm product ES-62 promotes health- and life-span in a high calorie diet accelerated mouse model of ageing. PLOS Pathogens, 16 (3). e1008391. ISSN 1553-7366

Text (Crowe-etal-PLOSP-2020-The-parasitic-worm-product-ES-62-promotes)
License: Creative Commons Attribution 4.0 logo

Download (11MB)| Preview


    Improvements in hygiene and health management have driven significant increases in human lifespan over the last 50 years. Frustratingly however, this extension of lifespan has not been matched by equivalent improvements in late-life health, not least due to the global pandemic in type-2 diabetes, obesity and cardiovascular disease, all ageing-associated conditions exacerbated and accelerated by widespread adoption of the high calorie Western diet (HCD). Recently, evidence has begun to emerge that parasitic worm infection might protect against such ageing-associated co-morbidities, as a serendipitous side-effect of their evolution of pro-survival, anti-inflammatory mechanisms. As a novel therapeutic strategy, we have therefore investigated the potential of ES-62, an anti-inflammatory secreted product of the filarial nematode Acanthocheilonema viteae, to improve healthspan (the period of life before diseases of ageing appear) by targeting the chronic inflammation that drives metabolic dysregulation underpinning ageing-induced ill-health. We administered ES-62 subcutaneously (at a dose of 1 μg/week) to C57BL/6J mice undergoing HCD-accelerated ageing throughout their lifespan, while subjecting the animals to analysis of 120 immunometabolic responses at various time-points. ES-62 improved a number of inflammatory parameters, but markedly, a range of pathophysiological, metabolic and microbiome parameters of ageing were also successfully targeted. Notably, ES-62-mediated promotion of healthspan in male and female HCD-mice was associated with different mechanisms and reflecting this, machine learning modelling identified sex-specific signatures predictive of ES-62 action against HCD-accelerated ageing. Remarkably, ES-62 substantially increased the median survival of male HCD-mice. This was not the case with female animals and unexpectedly, this difference between the two sexes could not be explained in terms of suppression of the chronic inflammation driving ageing, as ES-62 tended to be more effective in reducing this in female mice. Rather, the difference appeared to be associated with ES-62's additional ability to preferentially promote a healthier gut-metabolic tissue axis in male animals.